China Uranium Industry submitted an application for registration of its IPO on the Shenzhen Stock Exchange Main Board, focusing on the mining, smelting, sale, and trade of natural uranium.
On September 8th, China Uranium Corporation Limited (referred to as "China Uranium") applied for a change in IPO review status on the Shenzhen Stock Exchange main board to "registration submitted."
On September 8, China Uranium Corporation Limited (referred to as China Uranium) applied for the change of IPO review status on the Shenzhen Stock Exchange Main Board to "registration submission." China Securities Co., Ltd. is its sponsor and plans to raise 4.11 billion yuan.
The prospectus shows that China Uranium is a mining company focusing on the comprehensive utilization of natural uranium and radioactive co-associated mineral resources. During the reporting period, China Uranium mainly engaged in the mining, smelting, sales, and trading of natural uranium resources, as well as the comprehensive utilization and sales of radioactive co-associated mineral resources such as monazite and uranomolybdenite.
Based on resource advantages and production capabilities, the company has established a complete procurement, production, and sales system around the comprehensive utilization of natural uranium and radioactive co-associated mineral resources such as monazite and uranomolybdenite. It has also established stable cooperative relationships with major customers and suppliers.
China Uranium's external procurement mainly includes two parts: one is the procurement of various materials, services, and energy needed for the production of self-produced products, and the other is to ensure the supply of natural uranium for nuclear power by conducting natural uranium procurement domestically and internationally, as well as purchasing related services such as natural uranium agency, re-inspection, and transportation.
During the reporting period, China Uranium's main business included the comprehensive utilization of natural uranium and radioactive co-associated mineral resources, of which the natural uranium business accounted for 89.22%, 91.92%, and 93.35% of the main business income, respectively, which is the main source of income for China Uranium. The company's natural uranium business is divided into self-produced natural uranium product sales, purchased natural uranium product sales, and international natural uranium trade.
China Uranium has successively overcome various challenges in uranium mining such as multi-layered mining, the leaching of "three highs" (high calcium, high iron-aluminum, high mineralization) uranium ore, and recovery of scattered ore bodies, forming a complex sandstone uranium ore leaching development technology system with the third-generation in-situ uranium leaching technology as the benchmark. The company actively carries out overseas uranium resource development business, focusing on major uranium-producing areas in Africa, Asia, and other regions. The Rossing Uranium Mine in Namibia, where the company is located, ranked sixth in global uranium production in 2022.
In terms of finance, in 2022, 2023, and 2024, China Uranium achieved operating income of approximately 10.535 billion yuan, 14.801 billion yuan, and 17.279 billion yuan respectively. During the same period, the company achieved net profits of approximately 1.52 billion yuan, 1.511 billion yuan, and 1.712 billion yuan respectively.
Related Articles

Maintain the "buy" rating of GCL TECH (03800) and are optimistic about the significant improvement in the company's 25H2 performance.

FIRST SHANGHAI: Maintain a "Buy" rating on SHENZHOU INTL (02313) with a target price of HK$79.80.

HK Stock Market Move | DINGDANG HEALTH (09886) rose more than 5%, the company increased its investment in the weight loss market layout and advanced cooperation with original research pharmaceutical companies.
Maintain the "buy" rating of GCL TECH (03800) and are optimistic about the significant improvement in the company's 25H2 performance.

FIRST SHANGHAI: Maintain a "Buy" rating on SHENZHOU INTL (02313) with a target price of HK$79.80.

HK Stock Market Move | DINGDANG HEALTH (09886) rose more than 5%, the company increased its investment in the weight loss market layout and advanced cooperation with original research pharmaceutical companies.

RECOMMEND

Hong Kong Stock Concept Tracker|Oracle (ORCL.US) RPO Surge Ignites AI Computing Power Chain—Domestic Opportunities in Focus
11/09/2025

Southbound Capital Flows Shift: Profit-Taking on High-Flying Stocks and Accumulating Alibaba and Tence
11/09/2025

Anti-Involution Policies Deliver Results as August Price Indicators Improve
11/09/2025